Restoret is a tetravalent, tri-specific antibody administered via intravitreal injection to treat retinal diseases by agonizing the Wnt signaling pathway to restore and maintain the blood-retinal barrier and reduce vascular leakage.

EyeBio is developing a second bispecific agonist antibody asset targeting retinal diseases with a mechanism complementary to Restoret, aimed at preventing and treating vision loss from retinal vascular leakage.